NF1 alterations and activation of the RAS/MAPK signaling have been previously associated with the MES GBM subtype (Brennan et al., 2013; Verhaak et al., 2010; Wang et al., 2016; Wang et al., 2017). The gene discussed is NF1; the disease is glioblastoma.